dsm-firmenich speaks on UK Court of Appeal ruling on patent spat with Mara Renewables

Published: 11-Mar-2026
Regulatory

dsm-firmenich has talked to Nutraceutical Business Review about the UK Court of Appeal's decision to reject an appeal from the company against a 2025 ruling on one of its patents for producing microalgal DHA oil

You need to be a subscriber to read this article.
Click here to find out more.

The UK Court of Appeal has ruled in favour of Mara Renewables in a long-running patent dispute with dsm-firmenich.

The UK Court of Appeal rejected dsm-firmenich's appeal against a 2025 court ruling that one of its patents for producing microalgal docosahexaenoic acid (DHA) oil was invalid.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • DSM-Firmenich
See more

You may also like

Ingredients

dsm-firmenich strengthens HMO offering in Asia with new regulatory approvals

Read more
The company continues its regulatory success in Asia’s early life nutrition market with approval of four new HMOs in Malaysia and Thailand, alongside commercial authorisation of its 3’-SL ingredient in China

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Turmeric supplement adulteration: 22% of products contain undeclared ingredients, study finds New research reveals more than one in five turmeric-containing dietary supplements are adulterated with synthetic curcumin, undeclared dyes or diluents—posing serious quality, safety and commercial risks for nutraceutical brands
  2. Mycotechnology's Honey Truffle Sweet Protein achieves GRAS status The sweetening ingredient is now available commercially at scale for the US market, with the company positioning it as a solution for clean-label sugar reduction
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    dsm-firmenich speaks on UK Court of Appeal ruling on patent spat with Mara Renewables dsm-firmenich has talked to Nutraceutical Business Review about the UK Court of Appeal's decision to reject an appeal from the company against a 2025 ruling on one of its patents for producing microalgal DHA oil
  4. FDA reverses stance to confirm NMN is lawful for use in dietary supplements The agency’s decision marks a major policy shift, overturning its previous exclusion of NMN and clarifying the ingredient’s place in the supplement market
  5. Gain insight into skin ageing mechanisms driving nutraceutical innovation Exploring the science of skin ageing through a nutraceutical lens at the Anti-Ageing Skin Care Conference

Upcoming event

Making Nutraceuticals

21–22 April 2026 | Conference/Exhibition | Coventry, UK See all

You may also like

Ingredients

dsm-firmenich strengthens HMO offering in Asia with new regulatory approvals

The company continues its regulatory success in Asia’s early life nutrition market with approval of four new HMOs in Malaysia and Thailand, alongside commercial authorisation of its 3’-SL ingredient in China
Ingredients

dsm-firmenich's HMO nutraceutical gets the green light in Indonesia

dsm-firmenich's GLYCARE 2FL 9000 can now be marketed and sold within Indonesia, making it the 165th country with access to the company's HMO portfolio
Ingredients

dsm-firmenich's early life HMO ingredient, GLYCARE 2FL, approved for use in India

The early life human milk oligosaccharide ingredient is suitable for infants up to six months of age, and is designed to support gut health, while closely resembling breast milk
Manufacturing

dsm-firmenich successfully defends algal omega-3 tech patent

The UK High Court deemed that dsm-firmenich's algal processing technology, which produces high-purity DHA oils, was unlawfully used by Mara Renewables Corporation
Regulatory

dsm-firmenich's human milk oligosaccharide ingredients named as novel food ingredients in the UK and EU

The HMOs can now be incorporated into a range of food-grade products, such as supplements, infant formulas and foods for medical purposes
Ingredients

dsm-firmenich receives EU approval for calcidiol as a novel food

dsm's calcidiol ingredient can raise blood vitamin D levels in weeks, assisting in healthy immune function and overall wellbeing
Regulatory

dsm-firmenich successfully defends patent directed to proprietary DHA oils

This defends their sole manufacturing rights for specific algal nutritional lipids high in DHA and omega-3
Subscribe now